3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Head & Neck
1
Genitourinary
1
Endocrine
1
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
6
Brain Neoplasms
4
Neoplasms
3
Glioma
3
Thyroid Cancer, Papillary
2
Sarcoma
2
Salivary Gland Neoplasms
2
Neoplasms by Site
2
Neoplasms by Histologic Type
2
Neoplasm Metastasis
2
Melanoma
2
Lymphoproliferative Disorders
2
Hematologic Neoplasms
2
Central Nervous System Neoplasms
2
Wilms Tumor
1
Solid Tumors
1
Sarcoma, Ewing
1
Recurrence
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Neuroendocrine Tumors
1
Neuroblastoma
1
Nephroma, Mesoblastic
1
Neoplasms, Unknown Primary
1
Medulloblastoma
1
Lymphoma, Large-Cell, Anaplastic
1
Leukemia, Myeloid, Acute
1
Head and Neck Neoplasms
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Interventions
Cyclophosphamide
15
Temozolomide
11
Vincristine
10
Magnetic Resonance Spectroscopy
10
Cisplatin
10
Specimen Handling
8
Radiotherapy
8
Etoposide
8
X-Rays
6
Phantoms, Imaging
6
Carboplatin
6
Nuclear Medicine Department, Hospital
5
Lomustine
5
Radiation
4
Platinum
4
Methotrexate
4
Irinotecan
4
Filgrastim
4
Biopsy
4
1,2-diaminocyclohexaneplatinum II citrate
4
etoposide phosphate
3
Thiotepa
3
Nivolumab
3
Granulocyte Colony-Stimulating Factor
3
Celecoxib
3
Bevacizumab
3
Automobiles
3
ulixertinib
2
tipifarnib
2
tazemetostat
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Medulloblastoma
×
entrectinib
×
1 year
×
Clear all
NCT02650401
2026-03-25
STARTRK-NG
Hoffmann-La Roche
Phase 1/2
Active not recruiting
69 enrolled
1 FDA